N/A N=99 SmokefreeMOM: Reaching Pregnant Smokers With Health Information Via Text Messaging
Pregnancy · Smoking Cessation
Primary: Smoking Abstinence — 4; 8 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=43 Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Ketamine
Hemorrhage · Healthy
Primary: Cumulative Stress Index — 635; 649 mmHg x minutes
Phase 2 N=220 Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease
Agitation · Alzheimer's Disease
Primary: Change in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70…
Phase 2 N=39 COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111
Respiratory Distress Syndrome, Adult
Primary: Number of Subjects That Are Alive Without Respiratory Failure at Day 29. — 17; 14 Participants
Phase 2 N=121 A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
Allergic Conjunctivitis
Primary: Ocular Itching — 1.908; 1.925; 1.177; 2.758 units on a scale — p=0.0002
Phase 1 N=40 Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
Ebola Virus
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After the cAd3-EBO S Vaccine Administration — 3; 3; 6; 16 Participants
Phase 2 N=28 Mechlorethamine Induced Contact Dermatitis Avoidance Study
Cutaneous T-cell Lymphoma · Cutaneous T-cell Lymphoma Stage I · Mycosis Fungoides
Primary: Incidence of Moderate to Severe Contact Dermatitis by SCORD Scoring — 16; 11 patients
N/A N=50 SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma
Adenocarcinoma of the Pancreas
Primary: Local Progression-free Survival (LPFS) at 1-year — 85 percentage of participants
N/A N=294 Improvement of Patient Satisfaction and Overall Outcomes Using HealthLoop
Arthroplasty, Replacement, Knee · Arthroplasty, Replacement, Hip
Primary: Percentage of Participants Reporting a Problem Across al PPE-15 Domains — 12.6; 9.5 percent of participants
Phase 3 N=188 Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.
Hepatitis C
Primary: Number of Participants With Undetectable HCV RNA at 12 Weeks Post End of Treatment (SVR12) Following SOF/VEL for 6 Weeks as Compared With 12 Weeks in People With Recent…
Phase 3 N=154 A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension
Idiopathic Hypersomnia
Primary: Change in Epworth Sleepiness Scale (ESS) Score — 0.7; 7.4 score on a scale
Early Phase 1 N=29 Neurophysiological and Acute Pharmacological Studies in FXS Patients
Fragile X Syndrome
Primary: Change in EEG Relative Gamma Power — 0.0024; -0.0077; -0.0039; 0.0019 percent of power in gamma frequencies
N/A N=56 Clinical Evaluation of Daily Disposable Etafilcon A Cosmetic Contact Lenses
Visual Acuity
Primary: Proportion of Eyes With Distance Monocular Visual Acuity (logMAR) Lower Than 0.176 logMAR — 0.9998; 0.9998 proportion of eyes
Phase 2 N=87 Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma
Myeloma
Primary: Symptom Reduction — 26.02; 26.65 units on a scale*month
N/A N=576 Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology
Atrial Fibrillation
Primary: Number of Participants With Ischemic Stroke — 47 Participants